Skip to main content

Table 1 Patients’ characteristics of the study sample

From: A predictive model for recurrence after upfront surgery in patients with resectable pancreatic ductal adenocarcinoma (PDAC) by using preoperative clinical data and CT characteristics

Characteristic

Development Set (n = 141)

Validation Set (n = 77)

P Value

Age (years)a

63.43 ± 9.25

64.49 ± 10.40

0.277#

Gender

  

0.226

Male

Female

87(61.70)

54(38.30)

41(53.25)

36(46.75)

 

Tumor location

  

0.200

Head

88(62.41)

40(51.95)

 

Body

19(13.48)

17(22.08)

 

Tail

34(24.11)

20(25.97)

 

Laboratory results*

Cancer antigen 19–9(U/ml)

141.2(0.6–7767)

92.1(2–10,000)

0.573

Bilirubin (μmol/L)

13.8(3.7–436.1)

13.2(3.8–450.4)

0.334

Neutrophils/Lymphocytes

2.49 (0.52–13.25)

2.41(0.91–4.99)

0.479

Platelets/Lymphocytes ratio

134.12(61.07–463.33)

137.06(2.4–428)

0.985

C-reactive protein(mg/L)

1.2(0.3–32.9)

1.6(0.3–381.2)

0.294

Adjuvant therapy performedΣ

106(75.18)

59(76.62)

0.812

Type of pancreatic surgery£

  

0.924

Standard pancreaticoduodenectomy

54 (38.30)

29 (37.66)

 

Standard distal pancreatectomy

52 (36.88)

28 (36.36)

 

Extended pancreaticoduodenectomy

26 (18.44)

14 (18.18)

 

Extended distal pancreatectomy

8 (5.67)

6(7.79)

 

Standard total pancreatectomy

1 (0.71)

0(0.00)

 

Negative resection margin (R0)

140(99.29)

76()

0.663

Primary tumor (T) stage

  

0.900

T1

44 (31.21)

22(28.57)

 

T2

79 (56.03)

44(57.14)

 

T3

18(12.76)

11(14.29)

 

Regional lymph node (N) stage

  

0.064

N0

80 (56.74)

54(70.13)

 

N1

53 (37.59)

17(22.08)

 

N2

8 (5.67)

6(7.79)

 

AJCC prognostic stage group

  

0.090

IA

29(20.57)

12(15.58)

 

IB

41(29.08)

32(41.56)

 

IIA

10(7.09)

8(10.39)

 

IIB

51(36.17)

17(22.08)

 

III

9(6.38)

5(6.49)

 

IV

1(0.71)

3(3.90)

 

Tumor differentiation

  

0.108

Well differentiated

0(0.00)

0(0.00)

 

Moderately differentiated

70(49.65)

47(61.04)

 

Poorly or undifferentiated

71(50.35)

30(38.96)

 

Lymphovascular or microvascular invasion present

27(19.15)

18(23.38)

0.461

  1. Data are numbers, with percentages in parentheses, unless otherwise specified
  2. aData are means ± standard deviations
  3. *Data are medians, with ranges in parentheses
  4. Σ53 patients didn’t receive adjuvant therapy because of underlying diseases and perioperative complications
  5. £Type of surgery was classified as standard surgery or extended surgery involving concomitant vein or additional organ resection
  6. #Fisher’s exact test, χ2 test or one-way analysis of variance were used to compared data, excepted where indicated
Back to article page

BMC Medical Imaging

ISSN: 1471-2342

Contact us